Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer

Docetaxel (Taxotere) and vinorelbine (Navelbine) have both demonstrated activity as single agents for the treatment of patients with metastatic breast cancer and non-small-cell lung cancer. With 100 mg/m2 of docetaxel administered as a 1-hour intravenous infusion once every 3 weeks, projected median survival in previously untreated and treated patients with non-small-cell lung cancer is reported to be approximately 9 months. In addition, response rates have ranged from 23% to 36% and 17% to 21% in these respective patient populations. Preliminary studies indicate that in previously untreated patients with non-small-cell lung cancer, vinorelbine provides a survival benefit that is greater than best supportive care and similar to that of platinum-based chemotherapeutic regimens. Investigation into the use of these agents in combination is supported by synergy shown in preclinical models, nonoverlapping side-effect profiles, and the schedule independence of docetaxel. Preliminary results from phase I and II combination studies are encouraging, and no neurotoxicity has been observed. Based on these data, further study into the combined use of docetaxel and vinorelbine in patients with non-small-cell lung cancer is warranted.